$AXGN
Axogen, Inc. Stock $axgn

$axgn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000080592824000028 Filed on March 05, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$41.38M	$42.92M	$159.0M
YoY Change	12.86%	18.69%	14.74%
Cost Of Revenue	$8.758M	$9.640M	$31.14M
YoY Change	30.54%	38.57%	28.95%
Gross Profit	$32.62M	$33.28M	$127.9M
YoY Change	8.9%	13.95%	11.74%
Gross Profit Margin	78.83%	77.54%	80.42%
Selling, General & Admin	$29.77M	$29.18M	$121.0M
YoY Change	-2.76%	4.18%	3.43%
% of Gross Profit	91.27%	87.66%	94.63%
Research & Development	$7.409M	$7.301M	$28.33M
YoY Change	10.93%	7.19%	4.33%
% of Gross Profit	22.71%	21.94%	22.16%
Depreciation & Amortization	$1.520M	$1.617M	$4.218M
YoY Change	114.39%	127.11%	49.2%
% of Gross Profit	4.66%	4.86%	3.3%
Operating Expenses	$37.18M	$36.48M	$149.3M
YoY Change	-0.31%	4.77%	3.6%
Operating Profit	-$4.560M	-$3.194M	-$21.46M
YoY Change	-37.88%	-43.05%	-27.75%
Interest Expense	$2.326M	-$625.0K	$2.835M
YoY Change	14437.5%	-291.72%	354.33%
% of Operating Profit
Other Income/Expense, Net	-$2.075M	-$74.00K	-$254.0K
YoY Change	-877.15%	-44.36%	-133.47%
Pretax Income	-$6.635M	-$3.893M	-$21.72M
YoY Change	-6.21%	-28.11%	-24.98%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$6.635M	-$3.893M	-$21.72M
YoY Change	-6.21%	-28.11%	-24.98%
Net Earnings / Revenue	-16.04%	-9.07%	-13.66%
Basic Earnings Per Share	-$0.15		-$0.51
Diluted Earnings Per Share	-$0.15	-$0.09	-$0.51
COMMON SHARES
Basic Shares Outstanding	43.21M shares	43.04M shares	42.88M shares
Diluted Shares Outstanding	43.23M shares		42.88M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.63M	$31.02M	$31.02M
YoY Change	-53.43%	-36.41%	-36.41%
Cash & Equivalents	$15.71M	$31.02M	$31.02M
Short-Term Investments	$1.921M	$0.00	$0.00
Other Short-Term Assets	$9.181M	$8.813M	$8.813M
YoY Change	5.47%	7.54%	7.54%
Inventory	$27.64M	$23.02M	$23.02M
Prepaid Expenses
Receivables	$24.21M	$25.15M	$25.15M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$78.66M	$88.00M	$88.00M
YoY Change	-11.31%	-10.27%	-10.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$103.1M	$104.3M	$104.3M
YoY Change	6.36%	11.35%	11.35%
Goodwill
YoY Change
Intangibles	$4.768M	$4.531M
YoY Change	23.59%	24.17%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$107.9M	$108.8M	$108.8M
YoY Change	7.02%	11.83%	11.83%
TOTAL ASSETS
Total Short-Term Assets	$78.66M	$88.00M	$88.00M
Total Long-Term Assets	$107.9M	$108.8M	$108.8M
Total Assets	$186.5M	$196.8M	$196.8M
YoY Change	-1.56%	0.74%	0.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.29M	$11.77M	$11.77M
YoY Change	5.45%	31.35%	31.35%
Accrued Expenses	$1.639M	$18.65M	$18.65M
YoY Change	57.14%	1331.31%	26.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.000K	$6.000K	$6.000K
YoY Change	-28.57%	-14.29%	-14.29%
Total Short-Term Liabilities	$22.93M	$30.43M	$30.43M
YoY Change	7.98%	28.11%	28.11%
LONG-TERM LIABILITIES
Long-Term Debt	$46.83M	$46.60M	$46.62M
YoY Change	1.95%	1.95%	1.95%
Other Long-Term Liabilities	$23.59M	$24.11M	$24.11M
YoY Change	-4.81%	-3.19%	-3.19%
Total Long-Term Liabilities	$46.83M	$46.60M	$70.73M
YoY Change	1.95%	1.95%	0.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.93M	$30.43M	$30.43M
Total Long-Term Liabilities	$46.83M	$46.60M	$70.73M
Total Liabilities	$93.36M	$101.2M	$101.2M
YoY Change	1.52%	7.18%	7.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$287.9M	-$281.3M
YoY Change	7.98%	8.37%
Common Stock	$381.1M	$377.0M
YoY Change	4.65%	4.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$93.16M	$95.67M	$95.67M
YoY Change
Total Liabilities & Shareholders Equity	$186.5M	$196.8M	$196.8M
YoY Change	-1.56%	0.74%	0.74%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$6.635M	-$3.893M	-$21.72M
YoY Change	-6.21%	-28.11%	-24.98%
Depreciation, Depletion And Amortization	$1.520M	$1.617M	$4.218M
YoY Change	114.39%	127.11%	49.2%
Cash From Operating Activities	-$12.27M	-$211.0K	-$5.716M
YoY Change	65.24%	-115.49%	-64.42%
INVESTING ACTIVITIES
Capital Expenditures	$924.0K	$1.777M	$13.87M
YoY Change	-78.53%	-73.75%	-30.91%
Acquisitions
YoY Change
Other Investing Activities	-$1.910M	$1.500M	$34.17M
YoY Change	-150.65%	-73.02%	89.28%
Cash From Investing Activities	-$3.251M	-$277.0K	$19.25M
YoY Change	313.61%	-77.09%	-701.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$204.0K	418.0K	$1.954M
YoY Change	-67.77%	-48.59%	8.92%
NET CHANGE
Cash From Operating Activities	-$12.27M	-211.0K	-$5.716M
Cash From Investing Activities	-$3.251M	-277.0K	$19.25M
Cash From Financing Activities	$204.0K	418.0K	$1.954M
Net Change In Cash	-$15.31M	-70.00K	$15.49M
YoY Change	102.13%	-107.25%	-188.66%
FREE CASH FLOW
Cash From Operating Activities	-$12.27M	-$211.0K	-$5.716M
Capital Expenditures	$924.0K	$1.777M	$13.87M
Free Cash Flow	-$13.19M	-$1.988M	-$19.59M
YoY Change	12.48%	-63.23%	-45.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21462000	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	1487000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	569000	usd
CY2022	us-gaap	Interest Expense InterestExpense	624000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1356000	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-28000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000805928
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022	us-gaap	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense
CY2021	us-gaap	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense
CY2023	us-gaap	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20231231#LeaseLiabilityCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20231231#LeaseLiabilityCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20231231#LeaseLiabilitiesNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20231231#LeaseLiabilitiesNoncurrent
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20231231#LeaseLiabilityCurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20231231#LeaseLiabilityCurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20231231#LeaseLiabilitiesNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20231231#LeaseLiabilitiesNoncurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36046
CY2023	dei	Entity Registrant Name EntityRegistrantName	AXOGEN, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MN
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	13631 Progress Blvd., Suite 400
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	314414758	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43206246	shares
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31024000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15284000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	6002000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	6251000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	33505000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	337000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	650000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25147000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22186000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	23020000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	18905000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2811000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1944000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	88004000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98075000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	88730000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	79294000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15562000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14369000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4531000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3649000	usd
CY2023Q4	us-gaap	Assets Assets	196827000	usd
CY2022Q4	us-gaap	Assets Assets	195387000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	28883000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	22443000	usd
CY2023Q4	axgn	Lease Liability Current LeaseLiabilityCurrent	1547000	usd
CY2022Q4	axgn	Lease Liability Current LeaseLiabilityCurrent	1310000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30430000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23753000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	46603000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	45712000	usd
CY2023Q4	axgn	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	21142000	usd
CY2022Q4	axgn	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	20405000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2987000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4518000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	101162000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	94388000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43124496	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43124496	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42445517	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42445517	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	431000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	424000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	376530000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	360155000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-281296000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-259580000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	95665000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	100999000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	196827000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	195387000	usd
CY2023	us-gaap	Revenues Revenues	159012000	usd
CY2022	us-gaap	Revenues Revenues	138584000	usd
CY2021	us-gaap	Revenues Revenues	127358000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31138000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24147000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22931000	usd
CY2023	us-gaap	Gross Profit GrossProfit	127874000	usd
CY2022	us-gaap	Gross Profit GrossProfit	114437000	usd
CY2021	us-gaap	Gross Profit GrossProfit	104427000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	80228000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	73328000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24177000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2835000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1531000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1044000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-437000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-230000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-278000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-254000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	759000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1569000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21716000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28948000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26985000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42878543	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42083125	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41214889	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	123149000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10919000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2021	axgn	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	5467000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26985000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	112550000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15591000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2022	axgn	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	1806000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28948000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	100999000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14418000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2023	axgn	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	1964000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21716000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	95665000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21716000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28948000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26985000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4218000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2827000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2744000	usd
CY2023	axgn	Right Of Use Asset Amortization RightOfUseAssetAmortization	1062000	usd
CY2022	axgn	Right Of Use Asset Amortization RightOfUseAssetAmortization	1761000	usd
CY2021	axgn	Right Of Use Asset Amortization RightOfUseAssetAmortization	1795000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	273000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	265000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	202000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	891000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	891000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	831000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-56000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-271000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	612000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-41000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1939000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	1769000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	3314000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	666000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	228000	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-68000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1531000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1044000	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-28000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	14418000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	15591000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10919000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2691000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4639000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	499000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6054000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3656000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7478000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	867000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	84000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2435000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6509000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	660000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-270000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1269000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1841000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-463000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	3000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2000	usd
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-14000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5716000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16066000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13405000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13872000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20078000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27811000	usd
CY2023	axgn	Proceeds From Grantors Investing Activities ProceedsFromGrantorsInvestingActivities	0	usd
CY2022	axgn	Proceeds From Grantors Investing Activities ProceedsFromGrantorsInvestingActivities	0	usd
CY2021	axgn	Proceeds From Grantors Investing Activities ProceedsFromGrantorsInvestingActivities	950000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	10203000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	39247000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	68699000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	44374000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	57300000	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	72500000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1046000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1175000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	589000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19253000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3200000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23649000	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	12000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	15000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1964000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1806000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5467000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1954000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1794000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20452000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15491000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17472000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16602000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21535000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39007000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55609000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37026000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21535000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39007000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1944000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	495000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	704000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	866000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1420000	usd
CY2023	axgn	Embedded Derivative Associated With The Long Term Debt EmbeddedDerivativeAssociatedWithTheLongTermDebt	0	usd
CY2022	axgn	Embedded Derivative Associated With The Long Term Debt EmbeddedDerivativeAssociatedWithTheLongTermDebt	0	usd
CY2021	axgn	Embedded Derivative Associated With The Long Term Debt EmbeddedDerivativeAssociatedWithTheLongTermDebt	3037000	usd
CY2023	axgn	Noncash Right Of Use Assets And Operating Lease Liability NoncashRightOfUseAssetsAndOperatingLeaseLiability	2298000	usd
CY2022	axgn	Noncash Right Of Use Assets And Operating Lease Liability NoncashRightOfUseAssetsAndOperatingLeaseLiability	1018000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	6000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	19000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2021	axgn	Noncash Right Of Use Assets And Operating Lease Liability NoncashRightOfUseAssetsAndOperatingLeaseLiability	1375000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	407000	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	299000	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	418000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Nature of Business </span><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axogen, Inc. (together with its wholly-owned subsidiaries, the “Company”) was incorporated in Minnesota. Our business is focused on the science, development and commercialization of the technologies used for the peripheral nerve regeneration and repair. The Company's products include Avance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Graft, Axoguard Nerve Connector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Protector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axotouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Two-Point Discriminator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is headquartered in Florida. The Company has processing, warehousing, and distribution facilities in Ohio and Texas.</span></div>The Company manages its operations as a single operating segment. Substantially all of the Company's assets are maintained in the United States. The Company derives substantially all of its revenues from sales to customers in the United States.
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant estimates affecting the amounts reported or disclosed in the consolidated financial statements include the realizable value of inventories, the valuation of stock-based compensation and the valuation of derivative instruments and the fair value of debt instruments. Other estimates that affect the amounts reported or disclosed in the consolidated financial statements include the allowance for doubtful accounts, the useful life and recoverability of long-lived assets, incremental borrowing rates for operating leases, accounting for income taxes including the realizability of deferred tax assets and the related valuation allowance. The Company bases its estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</span></div>
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	30524000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31024000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	6002000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37026000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions and trade receivables. </span></div>The Company's products are sold on an uncollateralized basis and on credit terms.
CY2023	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	5285000	usd
CY2022	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	6155000	usd
CY2023	axgn	Contributions To Charitable Organization ContributionsToCharitableOrganization	0	usd
CY2022	axgn	Contributions To Charitable Organization ContributionsToCharitableOrganization	700000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12651000	usd
CY2023	axgn	Revenue From Contract With Customer Reduction For Distributor Customers RevenueFromContractWithCustomerReductionForDistributorCustomers	1056000	usd
CY2022	axgn	Revenue From Contract With Customer Reduction For Distributor Customers RevenueFromContractWithCustomerReductionForDistributorCustomers	856000	usd
CY2021	axgn	Revenue From Contract With Customer Reduction For Distributor Customers RevenueFromContractWithCustomerReductionForDistributorCustomers	736000	usd
CY2023	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	393000	usd
CY2022	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	158000	usd
CY2021	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	1164000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13545000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2120000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1026000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7355000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5228000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	23020000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	18905000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1939000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	1769000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	3314000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1342000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1221000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	138000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	131000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	102427000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	89590000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	13697000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	10296000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	88730000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	79294000	usd
CY2023	us-gaap	Depreciation Depreciation	4218000	usd
CY2022	us-gaap	Depreciation Depreciation	2827000	usd
CY2021	us-gaap	Depreciation Depreciation	2744000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6006000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1907000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4099000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4893000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1635000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3258000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	6438000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1907000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4531000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	5284000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1635000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3649000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	273000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	265000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	202000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11774000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8964000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3180000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4520000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	13929000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8959000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	28883000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	22443000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	20000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	22000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	3316000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	4077000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4326000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	520000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	72000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	1438000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1241000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	744000	usd
CY2023	us-gaap	Lease Cost LeaseCost	5282000	usd
CY2022	us-gaap	Lease Cost LeaseCost	5412000	usd
CY2021	us-gaap	Lease Cost LeaseCost	5104000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15562000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14369000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1541000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1303000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21123000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20387000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	28000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	41000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	6000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	19000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	18000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1099
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.1058
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.1322
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1191
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1099
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.1058
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.1322
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1191
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year One LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne	3925000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year Two LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo	4134000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year Three LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree	4269000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year Four LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour	3106000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year Five LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive	3104000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid After Year Five LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive	18566000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid LesseeOperatingAndFinancingLeaseLiabilityToBePaid	37104000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability Undiscounted Excess Amount LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount	14415000	usd
CY2023Q4	axgn	Operating And Financing Lease Liability OperatingAndFinancingLeaseLiability	22689000	usd
CY2023Q4	axgn	Operating And Financing Lease Liability Current OperatingAndFinancingLeaseLiabilityCurrent	1547000	usd
CY2023Q4	axgn	Operating And Financing Lease Liability Noncurrent OperatingAndFinancingLeaseLiabilityNoncurrent	21142000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3397000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4288000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	46603000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	45712000	usd
CY2023	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	5285000	usd
CY2022	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	6155000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	891000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	891000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	831000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	6002000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	6251000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year One LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne	3925000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year Three LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree	4269000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year Four LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour	3106000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year Five LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive	3104000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid After Year Five LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive	18566000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability To Be Paid LesseeOperatingAndFinancingLeaseLiabilityToBePaid	37104000	usd
CY2023Q4	axgn	Lessee Operating And Financing Lease Liability Undiscounted Excess Amount LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount	14415000	usd
CY2023Q4	axgn	Operating And Financing Lease Liability OperatingAndFinancingLeaseLiability	22689000	usd
CY2023Q4	axgn	Operating And Financing Lease Liability Current OperatingAndFinancingLeaseLiabilityCurrent	1547000	usd
CY2023Q4	axgn	Operating And Financing Lease Liability Noncurrent OperatingAndFinancingLeaseLiabilityNoncurrent	21142000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3397000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4288000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	46603000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	45712000	usd
CY2023	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	5285000	usd
CY2022	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	6155000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	891000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	891000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	831000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	6002000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	6251000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21716000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28948000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26985000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42878543	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42083125	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41214889	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42878543	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42083125	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41214889	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2023	axgn	Share Base Payment Arrangement Number Of Plans ShareBasePaymentArrangementNumberOfPlans	2	plan
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21716000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28948000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26985000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42878543	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42083125	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41214889	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42878543	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42083125	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41214889	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2023	axgn	Share Base Payment Arrangement Number Of Plans ShareBasePaymentArrangementNumberOfPlans	2	plan
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1710000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2643000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14167000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	41454000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42716000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	347000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	503000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	87000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	169000	usd
CY2023Q4	axgn	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	5867000	usd
CY2022Q4	axgn	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	5643000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6084000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5274000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	11530000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6357000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	772000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	1174000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	3000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	203000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	56000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	1010000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	66200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63049000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	978000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	983000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	51000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1710000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2643000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14167000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	41454000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42716000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	347000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	503000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	87000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	169000	usd
CY2023Q4	axgn	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	5867000	usd
CY2022Q4	axgn	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	5643000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6084000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5274000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	11530000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6357000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	772000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	1174000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	3000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	203000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	56000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	1010000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	66200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63049000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	978000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	983000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	51000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	17000	usd
CY2023Q4	axgn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	4031000	usd
CY2022Q4	axgn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	3744000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5060000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4740000	usd
CY2023Q4	axgn	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	61140000	usd
CY2022Q4	axgn	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	58309000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61140000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58309000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2831000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	17000	usd
CY2023Q4	axgn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	4031000	usd
CY2022Q4	axgn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	3744000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5060000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4740000	usd
CY2023Q4	axgn	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	61140000	usd
CY2022Q4	axgn	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	58309000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61140000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58309000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2831000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5058000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.087
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.071
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.016
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.130
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.175
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.247
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	41254000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	1538000	usd
CY2023Q4	us-gaap	Other Commitment Due In Second Year OtherCommitmentDueInSecondYear	1646000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5058000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	11530000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.087
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.071
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.016
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.130
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.175
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.247
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	41254000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	1538000	usd
CY2023Q4	us-gaap	Other Commitment Due In Second Year OtherCommitmentDueInSecondYear	1646000	usd

Files In Submission

Name	View Source	Status
0000805928-24-000028-index-headers.html	Edgar Link	pending
0000805928-24-000028-index.html	Edgar Link	pending
0000805928-24-000028.txt	Edgar Link	pending
0000805928-24-000028-xbrl.zip	Edgar Link	pending
a2023consent.htm	Edgar Link	pending
axgn-20231231.htm	Edgar Link	pending
axgn-20231231.xsd	Edgar Link	pending
axgn-20231231_g1.jpg	Edgar Link	pending
axgn-20231231_g2.jpg	Edgar Link	pending
axgnfy23q4ex311.htm	Edgar Link	pending
axgnfy23q4ex312.htm	Edgar Link	pending
axgnfy23q4ex321.htm	Edgar Link	pending
exhibit10105ninthamendme.htm	Edgar Link	pending
exhibit10105ninthamendme001.jpg	Edgar Link	pending
exhibit10105ninthamendme002.jpg	Edgar Link	pending
exhibit10105ninthamendme003.jpg	Edgar Link	pending
exhibit10105ninthamendme004.jpg	Edgar Link	pending
exhibit1051hanerveprotec.htm	Edgar Link	pending
exhibit1051hanerveprotec001.jpg	Edgar Link	pending
exhibit1051hanerveprotec002.jpg	Edgar Link	pending
exhibit1051hanerveprotec003.jpg	Edgar Link	pending
exhibit1051hanerveprotec004.jpg	Edgar Link	pending
exhibit1051hanerveprotec005.jpg	Edgar Link	pending
exhibit1051hanerveprotec006.jpg	Edgar Link	pending
exhibit1051hanerveprotec007.jpg	Edgar Link	pending
exhibit1051hanerveprotec008.jpg	Edgar Link	pending
exhibit1051hanerveprotec009.jpg	Edgar Link	pending
axgn-20231231_cal.xml	Edgar Link	unprocessable
axgn-20231231_def.xml	Edgar Link	unprocessable
axgn-20231231_lab.xml	Edgar Link	unprocessable
axgn-20231231_pre.xml	Edgar Link	unprocessable
exhibit1051hanerveprotec010.jpg	Edgar Link	pending
exhibit1051hanerveprotec011.jpg	Edgar Link	pending
exhibit1051hanerveprotec012.jpg	Edgar Link	pending
exhibit1051hanerveprotec013.jpg	Edgar Link	pending
exhibit1051hanerveprotec014.jpg	Edgar Link	pending
exhibit1051hanerveprotec015.jpg	Edgar Link	pending
exhibit1051hanerveprotec016.jpg	Edgar Link	pending
exhibit1051hanerveprotec017.jpg	Edgar Link	pending
exhibit1051hanerveprotec018.jpg	Edgar Link	pending
exhibit1051hanerveprotec019.jpg	Edgar Link	pending
exhibit1051hanerveprotec020.jpg	Edgar Link	pending
exhibit1051hanerveprotec021.jpg	Edgar Link	pending
exhibit1051hanerveprotec022.jpg	Edgar Link	pending
exhibit1051hanerveprotec023.jpg	Edgar Link	pending
exhibit1051hanerveprotec024.jpg	Edgar Link	pending
exhibit1051hanerveprotec025.jpg	Edgar Link	pending
exhibit1051hanerveprotec026.jpg	Edgar Link	pending
exhibit1052axogenincindu.htm	Edgar Link	pending
exhibit1052axogenincindu001.jpg	Edgar Link	pending
exhibit1052axogenincindu002.jpg	Edgar Link	pending
exhibit1052axogenincindu003.jpg	Edgar Link	pending
exhibit1052axogenincindu004.jpg	Edgar Link	pending
exhibit1052axogenincindu005.jpg	Edgar Link	pending
exhibit1052axogenincindu006.jpg	Edgar Link	pending
exhibit1052axogenincindu007.jpg	Edgar Link	pending
exhibit1052axogenincindu008.jpg	Edgar Link	pending
exhibit1052axogenincindu009.jpg	Edgar Link	pending
exhibit1052axogenincindu010.jpg	Edgar Link	pending
exhibit1052axogenincindu011.jpg	Edgar Link	pending
exhibit1052axogenincindu012.jpg	Edgar Link	pending
exhibit1052axogenincindu013.jpg	Edgar Link	pending
exhibit1052axogenincindu014.jpg	Edgar Link	pending
exhibit1052axogenincindu015.jpg	Edgar Link	pending
exhibit1052axogenincindu016.jpg	Edgar Link	pending
exhibit1052axogenincindu017.jpg	Edgar Link	pending
exhibit1052axogenincindu018.jpg	Edgar Link	pending
exhibit1052axogenincindu019.jpg	Edgar Link	pending
exhibit1052axogenincindu020.jpg	Edgar Link	pending
exhibit1052axogenincindu021.jpg	Edgar Link	pending
exhibit1052axogenincindu022.jpg	Edgar Link	pending
exhibit1052axogenincindu023.jpg	Edgar Link	pending
exhibit1052axogenincindu024.jpg	Edgar Link	pending
exhibit1052axogenincindu025.jpg	Edgar Link	pending
exhibit1052axogenincindu026.jpg	Edgar Link	pending
exhibit1052axogenincindu027.jpg	Edgar Link	pending
exhibit1053formofrestric.htm	Edgar Link	pending
exhibit1053formofrestric001.jpg	Edgar Link	pending
exhibit1053formofrestric002.jpg	Edgar Link	pending
exhibit1053formofrestric003.jpg	Edgar Link	pending
exhibit1053formofrestric004.jpg	Edgar Link	pending
exhibit1053formofrestric005.jpg	Edgar Link	pending
exhibit1053formofrestric006.jpg	Edgar Link	pending
exhibit1053formofrestric007.jpg	Edgar Link	pending
exhibit1053formofrestric008.jpg	Edgar Link	pending
exhibit1053formofrestric009.jpg	Edgar Link	pending
exhibit1053formofrestric010.jpg	Edgar Link	pending
exhibit1054formofperform.htm	Edgar Link	pending
exhibit1054formofperform001.jpg	Edgar Link	pending
exhibit1054formofperform002.jpg	Edgar Link	pending
exhibit1054formofperform003.jpg	Edgar Link	pending
exhibit1054formofperform004.jpg	Edgar Link	pending
exhibit1054formofperform005.jpg	Edgar Link	pending
exhibit1054formofperform006.jpg	Edgar Link	pending
exhibit1054formofperform007.jpg	Edgar Link	pending
exhibit1054formofperform008.jpg	Edgar Link	pending
exhibit1054formofperform009.jpg	Edgar Link	pending
exhibit1054formofperform010.jpg	Edgar Link	pending
exhibit1054formofperform011.jpg	Edgar Link	pending
exhibit1054formofperform012.jpg	Edgar Link	pending
exhibit1055formofperform.htm	Edgar Link	pending
exhibit1055formofperform001.jpg	Edgar Link	pending
exhibit1055formofperform002.jpg	Edgar Link	pending
exhibit1055formofperform003.jpg	Edgar Link	pending
exhibit1055formofperform004.jpg	Edgar Link	pending
exhibit1055formofperform005.jpg	Edgar Link	pending
exhibit1055formofperform006.jpg	Edgar Link	pending
exhibit1055formofperform007.jpg	Edgar Link	pending
exhibit1055formofperform008.jpg	Edgar Link	pending
exhibit1055formofperform009.jpg	Edgar Link	pending
exhibit1055formofperform010.jpg	Edgar Link	pending
exhibit1055formofperform011.jpg	Edgar Link	pending
exhibit1056employmentagr.htm	Edgar Link	pending
exhibit1056employmentagr001.jpg	Edgar Link	pending
exhibit1056employmentagr002.jpg	Edgar Link	pending
exhibit1056employmentagr003.jpg	Edgar Link	pending
exhibit1056employmentagr004.jpg	Edgar Link	pending
exhibit1056employmentagr005.jpg	Edgar Link	pending
exhibit1056employmentagr006.jpg	Edgar Link	pending
exhibit1056employmentagr007.jpg	Edgar Link	pending
exhibit1056employmentagr008.jpg	Edgar Link	pending
exhibit1056employmentagr009.jpg	Edgar Link	pending
exhibit1056employmentagr010.jpg	Edgar Link	pending
exhibit1056employmentagr011.jpg	Edgar Link	pending
exhibit1056employmentagr012.jpg	Edgar Link	pending
exhibit1056employmentagr013.jpg	Edgar Link	pending
exhibit1056employmentagr014.jpg	Edgar Link	pending
exhibit1056employmentagr015.jpg	Edgar Link	pending
exhibit1056employmentagr016.jpg	Edgar Link	pending
exhibit1056employmentagr017.jpg	Edgar Link	pending
exhibit1056employmentagr018.jpg	Edgar Link	pending
exhibit1056employmentagr019.jpg	Edgar Link	pending
exhibit1056employmentagr020.jpg	Edgar Link	pending
exhibit1056employmentagr021.jpg	Edgar Link	pending
exhibit1056employmentagr022.jpg	Edgar Link	pending
exhibit1056employmentagr023.jpg	Edgar Link	pending
exhibit1056employmentagr024.jpg	Edgar Link	pending
exhibit1056employmentagr025.jpg	Edgar Link	pending
exhibit1056employmentagr026.jpg	Edgar Link	pending
exhibit1056employmentagr027.jpg	Edgar Link	pending
exhibit1056employmentagr028.jpg	Edgar Link	pending
exhibit1056employmentagr029.jpg	Edgar Link	pending
exhibit1056employmentagr030.jpg	Edgar Link	pending
exhibit1056employmentagr031.jpg	Edgar Link	pending
exhibit1056employmentagr032.jpg	Edgar Link	pending
exhibit1056employmentagr033.jpg	Edgar Link	pending
exhibit1057amendmentno1t.htm	Edgar Link	pending
exhibit1057amendmentno1t001.jpg	Edgar Link	pending
exhibit1057amendmentno1t002.jpg	Edgar Link	pending
exhibit1058amendedipandn.htm	Edgar Link	pending
exhibit1058amendedipandn001.jpg	Edgar Link	pending
exhibit1058amendedipandn002.jpg	Edgar Link	pending
exhibit1058amendedipandn003.jpg	Edgar Link	pending
exhibit1058amendedipandn004.jpg	Edgar Link	pending
exhibit1058amendedipandn005.jpg	Edgar Link	pending
exhibit1058amendedipandn006.jpg	Edgar Link	pending
exhibit1058amendedipandn007.jpg	Edgar Link	pending
exhibit1058amendedipandn008.jpg	Edgar Link	pending
exhibit1058amendedipandn009.jpg	Edgar Link	pending
exhibit1058amendedipandn010.jpg	Edgar Link	pending
exhibit1058amendedipandn011.jpg	Edgar Link	pending
exhibit1058amendedipandn012.jpg	Edgar Link	pending
exhibit1058amendedipandn013.jpg	Edgar Link	pending
exhibit1059employmentagr.htm	Edgar Link	pending
exhibit1059employmentagr001.jpg	Edgar Link	pending
exhibit1059employmentagr002.jpg	Edgar Link	pending
exhibit1059employmentagr003.jpg	Edgar Link	pending
exhibit1059employmentagr004.jpg	Edgar Link	pending
exhibit1059employmentagr005.jpg	Edgar Link	pending
exhibit1059employmentagr006.jpg	Edgar Link	pending
exhibit1059employmentagr007.jpg	Edgar Link	pending
exhibit1059employmentagr008.jpg	Edgar Link	pending
exhibit1059employmentagr009.jpg	Edgar Link	pending
exhibit1059employmentagr010.jpg	Edgar Link	pending
exhibit1059employmentagr011.jpg	Edgar Link	pending
exhibit1059employmentagr012.jpg	Edgar Link	pending
exhibit1059employmentagr013.jpg	Edgar Link	pending
exhibit1059employmentagr014.jpg	Edgar Link	pending
exhibit1059employmentagr015.jpg	Edgar Link	pending
exhibit1059employmentagr016.jpg	Edgar Link	pending
exhibit1059employmentagr017.jpg	Edgar Link	pending
exhibit1059employmentagr018.jpg	Edgar Link	pending
exhibit1059employmentagr019.jpg	Edgar Link	pending
exhibit1059employmentagr020.jpg	Edgar Link	pending
exhibit1059employmentagr021.jpg	Edgar Link	pending
exhibit1059employmentagr022.jpg	Edgar Link	pending
exhibit1059employmentagr023.jpg	Edgar Link	pending
exhibit1059employmentagr024.jpg	Edgar Link	pending
exhibit1059employmentagr025.jpg	Edgar Link	pending
exhibit1059employmentagr026.jpg	Edgar Link	pending
exhibit1059employmentagr027.jpg	Edgar Link	pending
exhibit1059employmentagr028.jpg	Edgar Link	pending
exhibit1059employmentagr029.jpg	Edgar Link	pending
exhibit1059employmentagr030.jpg	Edgar Link	pending
exhibit1059employmentagr031.jpg	Edgar Link	pending
exhibit1060amendmentno1t.htm	Edgar Link	pending
exhibit1060amendmentno1t001.jpg	Edgar Link	pending
exhibit1060amendmentno1t002.jpg	Edgar Link	pending
exhibit1061amendedipandn.htm	Edgar Link	pending
exhibit1061amendedipandn001.jpg	Edgar Link	pending
exhibit1061amendedipandn002.jpg	Edgar Link	pending
exhibit1061amendedipandn003.jpg	Edgar Link	pending
exhibit1061amendedipandn004.jpg	Edgar Link	pending
exhibit1061amendedipandn005.jpg	Edgar Link	pending
exhibit1061amendedipandn006.jpg	Edgar Link	pending
exhibit1061amendedipandn007.jpg	Edgar Link	pending
exhibit1061amendedipandn008.jpg	Edgar Link	pending
exhibit1061amendedipandn009.jpg	Edgar Link	pending
exhibit1061amendedipandn010.jpg	Edgar Link	pending
exhibit1061amendedipandn011.jpg	Edgar Link	pending
exhibit1061amendedipandn012.jpg	Edgar Link	pending
exhibit1061amendedipandn013.jpg	Edgar Link	pending
exhibit1062employmentagr.htm	Edgar Link	pending
exhibit1062employmentagr001.jpg	Edgar Link	pending
exhibit1062employmentagr002.jpg	Edgar Link	pending
exhibit1062employmentagr003.jpg	Edgar Link	pending
exhibit1062employmentagr004.jpg	Edgar Link	pending
exhibit1062employmentagr005.jpg	Edgar Link	pending
exhibit1062employmentagr006.jpg	Edgar Link	pending
exhibit1062employmentagr007.jpg	Edgar Link	pending
exhibit1062employmentagr008.jpg	Edgar Link	pending
exhibit1062employmentagr009.jpg	Edgar Link	pending
exhibit1062employmentagr010.jpg	Edgar Link	pending
exhibit1062employmentagr011.jpg	Edgar Link	pending
exhibit1062employmentagr012.jpg	Edgar Link	pending
exhibit1062employmentagr013.jpg	Edgar Link	pending
exhibit1062employmentagr014.jpg	Edgar Link	pending
exhibit1062employmentagr015.jpg	Edgar Link	pending
exhibit1062employmentagr016.jpg	Edgar Link	pending
exhibit1062employmentagr017.jpg	Edgar Link	pending
exhibit1062employmentagr018.jpg	Edgar Link	pending
exhibit1062employmentagr019.jpg	Edgar Link	pending
exhibit1062employmentagr020.jpg	Edgar Link	pending
exhibit1062employmentagr021.jpg	Edgar Link	pending
exhibit1062employmentagr022.jpg	Edgar Link	pending
exhibit1062employmentagr023.jpg	Edgar Link	pending
exhibit1062employmentagr024.jpg	Edgar Link	pending
exhibit1062employmentagr025.jpg	Edgar Link	pending
exhibit1062employmentagr026.jpg	Edgar Link	pending
exhibit1062employmentagr027.jpg	Edgar Link	pending
exhibit1062employmentagr028.jpg	Edgar Link	pending
exhibit1062employmentagr029.jpg	Edgar Link	pending
exhibit1062employmentagr030.jpg	Edgar Link	pending
exhibit1062employmentagr031.jpg	Edgar Link	pending
exhibit1063amendmentno1t.htm	Edgar Link	pending
exhibit1063amendmentno1t001.jpg	Edgar Link	pending
exhibit1063amendmentno1t002.jpg	Edgar Link	pending
exhibit1064amendedipandn.htm	Edgar Link	pending
exhibit1064amendedipandn001.jpg	Edgar Link	pending
exhibit1064amendedipandn002.jpg	Edgar Link	pending
exhibit1064amendedipandn003.jpg	Edgar Link	pending
exhibit1064amendedipandn004.jpg	Edgar Link	pending
exhibit1064amendedipandn005.jpg	Edgar Link	pending
exhibit1064amendedipandn006.jpg	Edgar Link	pending
exhibit1064amendedipandn007.jpg	Edgar Link	pending
exhibit1064amendedipandn008.jpg	Edgar Link	pending
exhibit1064amendedipandn009.jpg	Edgar Link	pending
exhibit1064amendedipandn010.jpg	Edgar Link	pending
exhibit1064amendedipandn011.jpg	Edgar Link	pending
exhibit1064amendedipandn012.jpg	Edgar Link	pending
exhibit1064amendedipandn013.jpg	Edgar Link	pending
exhibit1097commerciallea.htm	Edgar Link	pending
exhibit1097commerciallea001.jpg	Edgar Link	pending
exhibit1097commerciallea002.jpg	Edgar Link	pending
exhibit1097commerciallea003.jpg	Edgar Link	pending
exhibit1097commerciallea004.jpg	Edgar Link	pending
exhibit1097commerciallea005.jpg	Edgar Link	pending
exhibit1097commerciallea006.jpg	Edgar Link	pending
exhibit1098commerciallea.htm	Edgar Link	pending
exhibit1098commerciallea001.jpg	Edgar Link	pending
exhibit1098commerciallea002.jpg	Edgar Link	pending
exhibit1098commerciallea003.jpg	Edgar Link	pending
exhibit1098commerciallea004.jpg	Edgar Link	pending
exhibit32amendedandresta.htm	Edgar Link	pending
exhibit32amendedandresta001.jpg	Edgar Link	pending
exhibit32amendedandresta002.jpg	Edgar Link	pending
exhibit32amendedandresta003.jpg	Edgar Link	pending
exhibit32amendedandresta004.jpg	Edgar Link	pending
exhibit32amendedandresta005.jpg	Edgar Link	pending
exhibit32amendedandresta006.jpg	Edgar Link	pending
exhibit32amendedandresta007.jpg	Edgar Link	pending
exhibit32amendedandresta008.jpg	Edgar Link	pending
exhibit32amendedandresta009.jpg	Edgar Link	pending
exhibit32amendedandresta010.jpg	Edgar Link	pending
exhibit32amendedandresta011.jpg	Edgar Link	pending
exhibit32amendedandresta012.jpg	Edgar Link	pending
exhibit32amendedandresta013.jpg	Edgar Link	pending
exhibit32amendedandresta014.jpg	Edgar Link	pending
exhibit32amendedandresta015.jpg	Edgar Link	pending
exhibit32amendedandresta016.jpg	Edgar Link	pending
exhibit97axogeninccompen.htm	Edgar Link	pending
exhibit97axogeninccompen001.jpg	Edgar Link	pending
exhibit97axogeninccompen002.jpg	Edgar Link	pending
exhibit97axogeninccompen003.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
subsidiariesofaxogen123120.htm	Edgar Link	pending
axgn-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AXGN
Axogen, Inc. Stock $axgn

2024 Q1 Form 10-K Financial Statement

#000080592824000028 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXGN Axogen, Inc. Stock $axgn

2024 Q1 Form 10-K Financial Statement

#000080592824000028 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXGN
Axogen, Inc. Stock $axgn